Overview

  • Product nameAnti-eIF4EBP2 antibody
    See all eIF4EBP2 primary antibodies
  • Description
    Rabbit polyclonal to eIF4EBP2
  • SpecificityDoes not react with eIF4E-BP1
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Rabbit, Cow, Dog, Human, Pig
    Predicted to work with: Chimpanzee
  • Immunogen

    Synthetic peptide:

    NNLNNHDRKHAVGDDAQFEMDI

    conjugated to KLH, corresponding to amino acids 99-120 of Human eIF4EBP2

  • Positive control
    • Rat Brain Tissue Extract

Properties

Applications

Our Abpromise guarantee covers the use of ab69529 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 4 µg/ml. Detects a band of approximately 17 and 20 kDa (native and phosphorylated form)(predicted molecular weight: 13 kDa).


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionRepressor of translation initiation involved in synaptic plasticity, learning and memory formation (By similarity). Regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form of EIF4EBP2 competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress translation. In contrast, hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation (PubMed:25533957). EIF4EBP2 is enriched in brain and acts as a regulator of synapse activity and neuronal stem cell renewal via its ability to repress translation initiation (By similarity). Mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways.
    • Sequence similaritiesBelongs to the eIF4E-binding protein family.
    • DomainThe TOS motif mediates interaction with RPTOR, leading to promote phosphorylation by mTORC1 complex.
      Intrinsically disordered protein that undergoes folding upon phosphorylation (PubMed:25533957). Hypophosphorylated form interacts strongly with EIF4E using (1) the YXXXXLPhi motif, that undergoes a disorder-to-helix transition upon binding and (2) the secondary EIF4E binding sites (residues 78-82) (PubMed:24207126, PubMed:25533957). Phosphorylation at Thr-37 and Thr-46 induces folding of region encompassing residues from Pro-18 to Arg-62 of into a four-stranded beta-domain that sequesters the helical YXXXXLPhi motif into a buried beta-strand, blocking accessibility to EIF4E. Protein phosphorylated at Thr-37 and Thr-46 is however unstable and subsequent phosphorylation at Ser-65, Thr-70 and Ser-83 is required to stabilize the fold, decreasing affinity for EIF4E by a factor of 4000 (PubMed:24207126, PubMed:25533957).
    • Post-translational
      modifications
      Phosphorylation at Thr-37, Thr-46, Ser-65, Thr-70 and Ser-83 is mediated by MTOR and corresponds to the hyperphosphorylated form: it abolishes binding to EIF4E by inducing folding of intrinsically disordered regions (PubMed:24207126, PubMed:25533957). First phosphorylated at Thr-37 and Thr-46 by MTOR, inducing folding of region encompassing residues from Pro-18 to Arg-62 of into a four-stranded beta-domain that sequesters the helical YXXXXLPhi motif into a partly buried beta-strand, blocking accessibility to EIF4E. Protein phosphorylated at Thr-37 and Thr-46 is however unstable and subsequent phosphorylation at Ser-65, Thr-70 and Ser-83 is required to stabilize the fold, decreasing affinity for EIF4E by a factor of 4000 (PubMed:24207126, PubMed:25533957). Phosphorylated in response to insulin, EGF and PDGF.
      Deamidated at Asn-99 and Asn-102 to aspartate (Asp) in brain. Deamidation promotes interaction with RPTOR, subsequent phosphorylation by mTORC1 and increased translation, leading to impair kinetics of excitatory synaptic transmission. Deamidation takes place during postnatal development, when the PI3K-Akt-mTOR signaling is reduced, suggesting it acts as a compensatory mechanism to promote translation despite attenuated PI3K-Akt-mTOR signaling in neuron development. Deamidation converts Asn residues into a mixture of Asp and isoaspartate; interactions with PCMT1 is required to prevent isoaspartate accumulation and convert isoaspartate to Asp.
    • Information by UniProt
    • Database links
    • Alternative names
      • 4E-BP2 antibody
      • 4EBP2 antibody
      • 4EBP2_HUMAN antibody
      • eIF4E binding protein 2 antibody
      • eIF4E-binding protein 2 antibody
      • Eif4ebp2 antibody
      • Eukaryotic translation initiation factor 4E binding protein 1 antibody
      • Eukaryotic translation initiation factor 4E-binding protein 2 antibody
      • PHASII antibody
      • phosphorylated, heat and acid stable regulated by insulin protein II antibody
      see all

    References for Anti-eIF4EBP2 antibody (ab69529)

    ab69529 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab69529.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"